Oxford Gene Technology Ltd. Release: How to Choose a Microarray Service Provider

Oxford, UK – 5th May 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has recently published a whitepaper entitled “10 essential questions to ask your microarray service provider”. The document, which is available to download at OGT’s website, suggests the 10 most important questions a researcher should ask when identifying which microarray service best meets their experimental requirements.

Each service provider is different, offering varying levels of experience and expertise, with some catering for many different applications and others dedicated only to specific areas. This often includes the ability to offer consultancy on various aspects of a study, such as suggesting ways to optimise array and experiment design, sample screening processes and data analysis. In addition, providers use a variety of array platforms and quality control methods, each affecting their suitability for different project requirements. These factors are highly important when deciding on the best service provider to utilise.

The whitepaper provided by OGT will help researchers make better informed decisions when it comes to choosing a microarray service provider, and can be downloaded for free at www.ogt.co.uk/whitepaper.

To find out more about the full range of products and services offered by OGT, visit www.ogt.co.uk.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk

W: www.ogt.co.uk

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies. CytoSure™: For research use only

This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

Back to news